Today: 4 February 2026
Subscribe
Browse Category

Investing News 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options.…
10 December 2025
·····
Newmont Stock Soars on Gold Rally: Latest NEM News, Analyst Forecasts and 2026 Outlook (10 December 2025)

Newmont Stock Soars on Gold Rally: Latest NEM News, Analyst Forecasts and 2026 Outlook (10 December 2025)

Newmont Corporation (NYSE: NEM) continues its spectacular run in 2025. On 10 December, the world’s largest gold miner’s share price climbed to about $94.09, up roughly 5.7% on the day and more than 130% year‑to‑date, as investors double down on the gold super‑cycle and Newmont’s aggressive restructuring and cost‑cutting program. Smartkarma Below is a deep dive into the latest news,…
10 December 2025
·····
Most Active Stocks Today: Nvidia, Tesla, PAVS, American Airlines and More Drive U.S. Market Volume on December 10, 2025

Most Active Stocks Today: Nvidia, Tesla, PAVS, American Airlines and More Drive U.S. Market Volume on December 10, 2025

The final U.S. trading days of 2025 are anything but sleepy. On Wednesday, December 10, 2025, the most active stocks today on the U.S. stock market span everything from mega‑cap AI leaders and streaming giants to ultra‑speculative penny stocks and battered turnaround stories. Below is a news‑style wrap that’s optimized for readers searching phrases like “most active stocks today,” “highest…
10 December 2025
····
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY).…
10 December 2025
··············
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Published: December 10, 2025 — U.S. pre‑market sessionAll data and news current as of early U.S. trading hours on Dec. 10, 2025. Fed Day Starts Quiet for Indexes, Wild for Individual Stocks Wall Street is waking up to a classic “calm on the surface, chaos underneath” kind of Fed day. S&P 500, Nasdaq 100, Dow Jones and Russell 2000 futures…
10 December 2025
··············
Google Stock Pre‑Market Today (Dec. 10, 2025): GOOGL, GOOG Price Action and Key Levels to Watch

Google Stock Pre‑Market Today (Dec. 10, 2025): GOOGL, GOOG Price Action and Key Levels to Watch

Alphabet’s “Google stock” is starting Wednesday’s session slightly on the back foot, with pre‑market trading reflecting a pause after an extraordinary AI‑driven rally and ahead of a key Federal Reserve decision later today. Below is a pre‑bell rundown of where Alphabet (tickers GOOGL and GOOG) is trading, the key support and resistance zones for today’s session, and the fresh news…
10 December 2025
·····
Tesla Stock Pre‑Market Today (December 10, 2025): Fresh Price Action Before the Bell

Tesla Stock Pre‑Market Today (December 10, 2025): Fresh Price Action Before the Bell

Tesla stock (NASDAQ: TSLA) is edging higher in pre‑market trading on Wednesday, December 10, 2025, as traders digest aggressive year‑end Model Y incentives, fresh headlines around Full Self‑Driving (FSD) and robotaxis, and the Federal Reserve’s final interest‑rate decision of the year. Public Key takeaways Pre‑market snapshot: TSLA trades in the mid‑$440s Tesla closed Tuesday’s regular session at roughly $445.17, up about 1.27% on…
10 December 2025
····
Stock Market Today, December 10, 2025: S&P 500, Nasdaq and Dow Futures Steady as Fed Rate Cut Decision Looms

Stock Market Today, December 10, 2025: S&P 500, Nasdaq and Dow Futures Steady as Fed Rate Cut Decision Looms

U.S. stock futures are hovering near the flat line early Wednesday as traders brace for one of the most closely watched Federal Reserve meetings in years and a packed day of macro data and mega-cap tech earnings. Between the European open and early U.S. pre-market trade, futures on the S&P 500, Nasdaq 100 and Dow Jones Industrial Average have oscillated in a…
10 December 2025
······
Best Stocks to Buy Now (December 10, 2025): 8 U.S. Stocks Positioned for an AI‑Driven, Rate‑Cut Era

Best Stocks to Buy Now (December 10, 2025): 8 U.S. Stocks Positioned for an AI‑Driven, Rate‑Cut Era

The U.S. stock market is entering the last stretch of 2025 near record highs. The S&P 500 is up mid‑teens percent for the year and just closed slightly lower as investors wait for the Federal Reserve’s December 9–10 policy decision, with futures still pricing in a high probability of a 25‑basis‑point rate cut. Reuters At the same time, the market…
10 December 2025
·····
GE Vernova (GEV) Stock Soars on New 2026 Outlook, Dividend Hike and $10 Billion Buyback

GE Vernova (GEV) Stock Soars on New 2026 Outlook, Dividend Hike and $10 Billion Buyback

Date: December 10, 2025 GE Vernova (NYSE: GEV) jumped after its 2025 Investor Update, where the energy technology company raised its 2026 and 2028 outlook, doubled its dividend, and expanded its buyback. Here’s what the latest guidance, analyst reactions and valuation signals mean for investors. GE Vernova stock today: price, performance and context GE Vernova Inc. (NYSE: GEV) is extending…
10 December 2025
·····
Robinhood (HOOD) Stock on December 10, 2025: 164% Rally, Indonesia Expansion and Insider Selling – Is It Still a Buy?

Robinhood (HOOD) Stock on December 10, 2025: 164% Rally, Indonesia Expansion and Insider Selling – Is It Still a Buy?

Robinhood Markets (NASDAQ: HOOD) is back in the spotlight on Wednesday, December 10, 2025, as the trading app’s shares hover in the mid‑$130s, not far below their 52‑week high of $153.86. Over the last 12 months, the stock has climbed roughly 164%, and it’s up nearly 270% year to date, turning Robinhood from a post‑meme punchline into one of the…
10 December 2025
····
Shell Plc (SHEL) Stock on December 10, 2025: Price, Buybacks, Dividend and 2026 Outlook

Shell Plc (SHEL) Stock on December 10, 2025: Price, Buybacks, Dividend and 2026 Outlook

Updated: December 10, 2025 Shell Plc stock is trading close to the top of its 52‑week range as investors digest a powerful mix of hefty buybacks, a nearly 4% dividend yield, softening oil prices and fresh deal headlines in the Gulf of Mexico and Brazil. At the same time, analysts broadly see moderate upside for 2026, while warning that the…
10 December 2025
·····
1 … 403 404 405 406 407 … 564

Stock Market Today

  • Poxel S.A. Stock Drops 17.19% on EURONEXT Amid Weak Biotech Momentum
    February 4, 2026, 7:59 AM EST. Poxel S.A. (POXEL.PA) shares plunged 17.19% intraday to €0.316 on EURONEXT on 04 Feb 2026, pressured by weak near-term momentum in the biotech sector and concerns over small market cap of €18.7 million. Trading volume surged above the 50-day average, highlighting increased selling. Key financials indicate persistent losses, with EPS at -0.26 and a negative price-to-earnings ratio. Technical indicators suggest short-term support near €0.31 but volatile trading ahead of anticipated earnings on 25 Mar 2026. Meyka AI assigns a hold rating with a score of 60.87/100, projecting a price decline to €0.26 over the year while noting fundamental and liquidity challenges for the clinical-stage biotech.
Go toTop